Humacyte Inc (HUMA) — 13F Holders Deep Dive (Q2 2026)

HUMA ranks #3440 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

167 institutions disclose a position in HUMA, but none treat it as a major bet — even Lion Point Capital, LP, its most concentrated holder, allocates just 2.4% of its own portfolio to it.

ANTIPODES PARTNERS Ltd has added to its HUMA position for two straight quarters, increasing it by $7.9M to reach $7.9M today.

BlackRock has trimmed its HUMA position for two straight quarters, cutting it by $7.1M while still holding $3.8M.

HUMA is down 5.1% today, but institutions show net buying of $14.0M this quarter — a divergence between today's price move and the underlying institutional flow.

HUMA reported a net loss of $96.7M over the trailing twelve months.

• Not yet profitable — net loss of $96.7M over the trailing twelve months
• Revenue grew 159.3% year over year
• Net income declined year over year, from -$58.7M to -$96.7M
• Operating cash flow was negative, using $105.0M in cash
• Current ratio of 3.69x — enough short-term assets to cover short-term liabilities
• Liabilities run 36.43x equity — a highly leveraged balance sheet worth noting